Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Common Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Common Equity for 4 consecutive years, with $158.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 1.5% to $158.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.9 million through Dec 2025, down 1.5% year-over-year, with the annual reading at $158.9 million for FY2025, 1.5% down from the prior year.
  • Common Equity for Q4 2025 was $158.9 million at Century Therapeutics, down from $176.3 million in the prior quarter.
  • The five-year high for Common Equity was $386.7 million in Q1 2022, with the low at $158.9 million in Q4 2025.
  • Average Common Equity over 4 years is $240.6 million, with a median of $220.7 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 38.97% in 2023, then soared 35.17% in 2025.
  • Over 4 years, Common Equity stood at $302.7 million in 2022, then plummeted by 38.97% to $184.8 million in 2023, then fell by 12.66% to $161.4 million in 2024, then fell by 1.5% to $158.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $158.9 million, $176.3 million, and $209.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.